Kingworld Medicines Group Announces Major R&D and Distribution Agreements for New Chinese Medicine Products
Key Highlights
- Kingworld Medicines Group Limited has entered into significant memoranda of understanding (MOUs) regarding two innovative Chinese medicine products: “Zizhu Leaf Cleansing Solution” and “Modified Gastrodia Brain-Health Formula”.
- The MOUs cover both research and development (R&D) collaboration and exclusive distribution rights for these products in Hong Kong, Mainland China, and through cross-border e-commerce channels.
- The agreements are with Morning Gold Medicine Company Limited (a company controlled by the Chairman and an Executive Director of Kingworld) and Dongguan Hospital of Guangzhou University of Chinese Medicine, a prestigious Grade III Class A Chinese medicine hospital.
- Both R&D and distribution arrangements are currently non-legally binding and subject to definitive agreements.
- The arrangements constitute connected transactions under HKEX rules, and the company will comply with all applicable regulations.
Details of the R&D Collaboration
On 11 June 2026, Morning Gold (a connected person of Kingworld Medicines, 51% held by Chairman Mr. Zhao Li Sheng and 49% by Executive Director Ms. Chan Lok San) entered into MOUs with Dongguan City Chinese Medicine Hospital to jointly research, develop, and commercialize the two products.
- Zizhu Leaf Cleansing Solution: A traditional Lingnan formula with clinical use at Dongguan Hospital, particularly for skin burns, diabetic foot ulcers, and pressure sores. Accumulated application experience and data are available.
- Modified Gastrodia Brain-Health Formula: Based on “Gastrodia Brain-Health Granules,” previously used for symptoms such as dizziness, headache, memory impairment, and insomnia associated with wind-phlegm disturbance. Research for broader brain and nervous system applications is ongoing.
Key R&D Terms:
- Morning Gold will provide initial and ongoing funding for the projects and seek additional research funding in Hong Kong and Mainland China.
- Dongguan Hospital will contribute technological achievements. For “Modified Gastrodia Brain-Health Formula”, new intellectual property will be jointly owned, with Morning Gold as the first applicant and Dongguan Hospital as co-applicant. For “Zizhu Leaf Cleansing Solution,” new patents will be registered in Morning Gold’s name, with Dongguan Hospital as a technical alliance partner.
- In case of termination, IP ownership and allocation will be defined in future definitive agreements.
- Commercial terms include a one-off technology transfer fee and a profit-sharing mechanism: upon commercialization in Mainland China, Morning Gold will receive 80% and Dongguan Hospital 20% of net profits for ten years.
- Products will first be registered in Hong Kong as proprietary Chinese medicines, then production and commercialization will begin, with Morning Gold (via its subsidiary or Kingworld Medicines) leading distribution and Dongguan Hospital supporting clinical applications and production.
- Upon gathering sufficient clinical data, Morning Gold will pursue drug registration in Mainland China, aiming to obtain national pharmaceutical registration certificates.
Exclusive Distribution MOUs
On the same day, Morning Gold and Kingworld Medicines signed MOUs granting Kingworld and/or its subsidiaries exclusive rights to distribute both products in Hong Kong, Mainland China, and via cross-border e-commerce.
- The exclusive distribution covers all channels: retail, hospital, and online platforms. Morning Gold will not appoint any other distributors within the agreed territory and channels during the term.
- Kingworld will be responsible for all marketing, distribution network development, and sales, while Morning Gold will ensure compliant production, stable supply, and provide necessary documentation.
- Distribution will proceed in phases, starting in Hong Kong and cross-border channels after HKC registration, followed by Mainland China after obtaining national drug registration.
- Detailed terms will be set out in definitive distribution agreements.
Important Information for Shareholders and Investors
- Price-sensitive: The MOUs represent significant growth opportunities for Kingworld Medicines, potentially expanding its product portfolio and market reach in the lucrative Chinese medicine sector. If definitive agreements are executed and the products succeed in registration and commercialization, this could have a substantial positive impact on the company’s revenues and share value.
- Risks: Both the R&D and Distribution MOUs are non-legally binding. There is no assurance the transactions will proceed as contemplated or at all. Investors should be cautious and monitor further announcements regarding definitive agreements.
- Regulatory risk: The products may not have obtained all required regulatory approvals for commercial or medical use in any jurisdiction. All forward-looking statements are subject to regulatory outcomes.
- Connected Transactions: As Morning Gold is a connected party, these deals will constitute connected transactions under HKEX Listing Rules, which may require additional compliance and approval.
Conclusion
These proposed collaborations and distribution arrangements, if finalized, could mark a major expansion for Kingworld Medicines into high-potential Chinese medicine markets. Investors should watch for further updates as these MOUs progress toward definitive agreements.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. The details provided are based on company announcements and may be subject to change pending regulatory approval and execution of definitive agreements. Investors should exercise caution and conduct their own due diligence before making investment decisions.
金活醫藥集團公佈重大中藥產品研發及獨家分銷諒解備忘錄
重點內容
- 金活醫藥集團有限公司就兩款創新中藥產品——「紫竹葉清洗液」及「改良天麻腦健康方」簽訂重要諒解備忘錄（MOU）。
- 備忘錄涵蓋研發合作及獨家分銷權，覆蓋香港、中國內地及跨境電商渠道。
- 合作方包括晨金醫藥有限公司（由董事長趙利生及執行董事陳樂珊控股）及東莞市中醫院（國家三級甲等中醫綜合醫院）。
- 所有安排暫屬非具法律約束力，須待正式協議簽訂。
- 有關安排屬於關連交易，公司將遵守所有相關監管要求。
研發合作詳情
2026年6月11日，晨金（董事長趙利生持有51%，執行董事陳樂珊持有49%）與東莞市中醫院簽訂MOU，攜手研發、臨床、監管註冊及商業化兩款產品。
- 紫竹葉清洗液：嶺南經典方劑，已於東莞市中醫院臨床應用，積累應用經驗，特別用於皮膚燒傷、糖尿病足潰瘍及壓瘡等。
- 改良天麻腦健康方：源自「天麻腦健康顆粒」，臨床應用於頭暈、頭痛、記憶力下降及失眠等症狀，目前正處於腦神經應用的觀察研究階段。
主要研發條款：
- 晨金負責項目前期及持續資金，雙方積極申請中港兩地研發資助。
- 東莞市中醫院提供技術成果，「改良天麻腦健康方」的知識產權將由雙方共同擁有，晨金為首申請人，東莞市中醫院為共同申請人；「紫竹葉清洗液」的新專利則歸晨金所有，東莞市中醫院為技術聯盟方。
- 若項目終止，知識產權歸屬將由最終協議確定。
- 商業條款包括一次性技術轉讓費及利潤分成：產品在內地商業化後，晨金獲80%，東莞市中醫院獲20%，為期十年。
- 產品先於香港註冊為中成藥，隨後生產及商業化，晨金（或其子公司／金活醫藥）負責分銷，東莞市中醫院支援臨床與生產，並累積內地註冊所需臨床數據。
- 數據充足後，晨金將於內地申請藥品註冊，取得國家藥品註冊證書。
獨家分銷諒解備忘錄
同日，晨金與金活醫藥簽訂MOU，授予金活醫藥及其子公司於香港、內地及跨境電商渠道的獨家分銷權。
- 獨家分銷涵蓋零售、醫院、網上平台，晨金於期間內不會委任其他分銷商。
- 金活醫藥負責市場推廣、分銷網絡及銷售，晨金確保合規生產、穩定供應及提供文件支援。
- 分階段推進，先於香港及跨境渠道分銷（完成HKC註冊後），再拓展至內地（取得國家藥品註冊後）。
- 具體細節將於正式分銷協議中訂明。
對股東及投資者的重要提示
- 具價格敏感性： 有關MOU為金活醫藥帶來增長機遇，若協議落實並產品成功註冊及商業化，對公司收入及股價或有重大正面影響。
- 風險： 目前所有備忘錄均為非法律約束性，交易未必如期進行，投資者需密切留意後續公告。
- 監管風險： 產品或未取得所有所需監管批准，前景受監管因素影響。
- 關連交易： 晨金屬於關連人士，相關交易將構成上市規則下的關連交易或需獲批准。
總結
若有關合作及分銷安排落實，將助金活醫藥大幅拓展中藥新市場。投資者應密切留意公司進一步公告。
免責聲明： 本文僅供資料參考，並不構成投資建議。有關內容以公司公告為依據，如有變動以監管批准及正式協議為準。投資者應審慎評估並作獨立判斷。
